Synagis (Pediatric RSV) - Forecast and Market Analysis to 2022
London (PRWEB) September 18, 2013 -- Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, “Synagis (Pediatric RSV) - Forecast and Market Analysis to 2022”. Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. The virus is spread through the air by an infected person’s sneeze or cough, or through direct and indirect contact with nasal secretions of an infected person. The majority of RSV infections present as mild upper respiratory illnesses that often self-resolve within two weeks, but about 1% of the cases develop serious lower respiratory complications requiring hospitalization. Children under the age of two with certain health conditions are most at risk for severe RSV infections and are therefore recommended to receive RSV prophylaxis treatments. The only FDA-approved prophylactic intervention in the US is AstraZeneca’s Synagis (palivizumab), a humanized monoclonal antibody against the fusion protein of the virus.
AstraZeneca’s Synagis (palivizumab) is a humanized mouse mAb used for the prevention of serious lower respiratory tract disease as a result of RSV infection in high-risk pediatric patients under the age of two. Synagis’ mechanism of action involves the binding of the antibody to the viral F protein. Synagis received FDA approval in 1998, and by 2002 was approved in all the seven major markets (7MM) (US, France, Italy, Germany, Spain, UK, and Japan) for the prophylaxis of infants at high risk of severe RSV infection. Today, Synagis is approved in 83 countries worldwide (AstraZeneca, 2012). Synagis is the only immunoprophylaxis approved for pediatric patients.
Scope
- Overview of RSV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Synagis including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Synagis for the US from 2012 to 2022.
- Sales information covered for the US
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for RSV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Synagis performance
- Obtain sales forecast for Synagis from 2012-2022 the US
Table of Contents
1 Table of Contents 7
1.1 List of Tables 9
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Pathophysiology 15
3.1.2 Prognosis 16
3.1.3 Quality of Life 16
3.2 Symptoms 17
4 Disease Management 18
4.1 Treatment Overview 18
4.2 Diagnosis 20
4.3 Clinical Practice 21
5 Competitive Assessment 25
5.1 Overview 25
6 Synagis (palivizumab) 27
6.1 Overview 27
6.2 Efficacy 28
6.3 Safety 29
6.4 SWOT Analysis 30
6.5 Forecast 31
7 Appendix 32
7.1 Bibliography 32
7.2 Abbreviations 38
7.3 Methodology 40
7.4 Forecasting Methodology 40
7.4.1 Number of eligible patients for prophylaxis 40
7.4.2 Utilization rates of Synagis 41
7.4.3 Patient share and generic erosion 42
7.4.4 Weight of high risk infants 42
7.4.5 Cost per day 42
7.4.6 Number of prophylaxis days per year 42
7.4.7 Annual cost of therapy 43
7.4.8 Patient compliance 43
7.4.9 Total sales 43
7.4.10 Drugs Included in Each Therapeutic Class 43
7.4.11 Launch and Patent Expiry Dates 43
7.4.12 General Pricing Assumptions 44
7.4.13 Individual Drug Assumptions 44
7.5 Physicians and Specialists Included in this Study 45
7.6 About the Authors 46
7.6.1 Authors 46
7.6.2 Epidemiologist 47
7.6.3 Global Head of Healthcare 47
7.7 About GlobalData 48
7.8 Contact Us 48
7.9 Disclaimer 48
List of Tables
Table 1: Symptoms of RSV infection 17
Table 2: Treatment Guidelines for Pediatric RSV Prevention 18
Table 3: Most Prescribed Prophylactics for Pediatric RSV in the US, 2013 18
Table 4: Leading Prophylactic Treatments for Pediatric RSV, 2012 26
Table 5: Product Profile – Synagis 28
Table 6: Synagis SWOT Analysis, 2012 30
Table 7: US Sales Forecasts ($m) for Synagis, 2012–2022 31
Table 8: Key Launch Date 43
Table 9: Key Patent Expiries 43
List of Figures
Figure 1: Schematic Representation of the RSV Virion 13
Read the full report:
Synagis (Pediatric RSV) - Forecast and Market Analysis to 2022
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com
Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]
Share this article